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Background: The recent emergence of extensively multidrug-resistant Mycobacterium tuberculosis strains has
further complicated the control of tuberculosis. There is an urgent need for the development of new molecular
candidates antitubercular drugs. Medicinal plants have been an excellent source of leads for the development of
drugs. The aim of this study was to evaluate the in vitro activity of 28 alcoholic extracts and essential oils of native
and exotic Brazilian plants against Mycobacterium tuberculosis and to further study these extracts through chemical
fractionation, the isolation of their constituents, and an evaluation of the in vivo acute toxicity of the active extracts.
To the best of our knowledge this is the first chemical characterization, antituberculosis activity and acute toxicity
evaluation of Annona sylvatica.
Methods: The anti-mycobacterial activity of these extracts and their constituent compounds was evaluated using
the resazurin reduction microtiter assay (REMA). To investigate the acute toxicity of these extracts in vivo, female
Swiss mice were treated with the extracts at doses of 500, 1000 and 2000 mg · kg−1 of body weight. The extracts
were characterized by LC-MS, and the constituents were isolated and identified by chromatographic analysis of
spectroscopic data.
Results: Of the 28 extracts, the methanol extract obtained from the leaves of Annona sylvatica showed
anti-mycobacterial activity with an minimal inhibitory concentration (MIC) of 184.33 μg/mL, and the ethyl acetate
fraction (EAF) resulting from liquid-liquid partitioning of the A. sylvatica extract showed an MIC of 115.2 μg/mL.
The characterization of this extract by LC-MS identified flavonoids and acetogenins as its main constituents. The
phytochemical study of the A. sylvatica EAF resulted in the isolation of quercetin, luteolin, and almunequin.
Conclusions: Among the compounds isolated from the EAF, luteolin and almunequin were the most promising,
with MICs of 236.8 μg/mL (827.28 μM) and 209.9 μg/mL (328.48 μM), respectively. The acute administration of
the EAF fraction in doses of 500, 1000, and 2000 mg · kg−1 of body weight did not cause signs of toxicity in the
treated animals.
Keywords: Mycobacterium tuberculosis, Annona sylvatica, Resazurin reduction toxicity, Luteolin, AlmunequinBackground
Tuberculosis remains an important public health problem
and a major cause of death worldwide; it is responsible for
approximately one million deaths every year [1,2]. Due to
the reduced effectiveness of current drugs resulting from
the emergence of multidrug-resistant strains (MDRTB)
and co-infection with HIV, there is an urgent need to de-
velop new natural or synthetic antitubercular drugs [3-5].* Correspondence: juliocroda@ufgd.edu.br
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unless otherwise stated.The use of medicinal plants is important throughout the
world, especially in traditional or alternative medicine. The
search for active plant-derived compounds is a modern ap-
proach to drug discovery, especially in tropical regions with
abundant flora. In underdeveloped or developing countries,
medicines derived from plants are important weapons
against serious diseases. Traditional medicine has enabled
the treatment of common illnesses in approximately
60 to 80% of the world population [6,7]. The extrac-
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represent the first steps toward identifying natural
products or semi-synthetic derivatives that may provide
new antitubercular drugs [8-12].
Research in the area of natural products has intensified,
especially in the search for compounds and plant species
that are active against Mycobacterium tuberculosis and
with the development of easier, faster, and safer screening
techniques [13-26]. Previous studies have demonstrated
that several plants are active against M. tuberculosis,
such as Clavija procera B. Ståhl, which has been
shown to be active even against resistant strains [14];
Abelmoschus esculentus Moench; Faurea saligna Harv;
Parinari curatellifolia Planch ex Benth [15]; Maerua
edulis (Gilg & Gilg-Ben.) DeWolf; Securidaca longepedun-
culata Fres.; Tabernaemontana elegans Stapf; Zanthoxylum
capense (Thunb.) Harv. [16]; Aristolochia taliscana Hook
[17]; and Acorus calamus L. var. americanus [18].
According to the screening program for new antitu-
bercular drugs developed by the National Institutes of
Health of the United States, all compounds must be used
in both in vitro and in vivo models to evaluate their poten-
tial as antitubercular agents [27].
This study was conducted as a preliminary in vitro screen-
ing of 28 plant extracts and three essential oils against M.
tuberculosis using the REMA assay. The characterization
of the active extract by LC-MS, the isolation of the main
constituents of this extract, and the subsequent evaluation
of the anti-M. tuberculosis activity and in vivo acute
toxicity of these extracts were also performed.Methods
Plant material
Different species of Asteraceae, Anacardiaceae, Annona-
ceae, Bignoniaceae, Euphorbiaceae, Fabaceae, Gesneriaceae,
Malvaceae, Meliaceae, Myrtaceae, Rubiaceae, Sapindaceae,
and Tropaeolaceae were collected in Dourados, Mato
Grosso do Sul, and Maringá and Curitiba, Paraná, Brazil.
The plants were identified by Dr. Armando Carlos Cervi,
Dr. Maria Conceição de Souza, and Dr. Zefa Valdevina
Pereira. A voucher specimen of each species was identi-
fied and deposited in the herbarium of each institution
(Table 1).Preparation of extracts
The plants were air-dried at room temperature and
ground with a pestle and mortar. Approximately 300 g
of each sample was then exhaustively extracted by
macerating the sample with 1.5 L of the appropriate
solvents (Table 1) at room temperature (five times for
each species at 48 h intervals). The crude extract was
then isolated by the evaporation of the solvent under
vacuum on a rotary evaporator. For subsequent studies,the extracts were diluted in DMSO (dimethyl sulfoxide) at
10,000 μg/mL.
Fractionation and compound isolation
An extract that exhibited potential activity against
Mycobacterium tuberculosis was dissolved in methanol:
water (1:1) and partitioned with chloroform and ethyl
acetate to yield the chloroform fraction (CF), ethyl acetate
fraction (EAF), and hydromethanol fraction (HMF) after
the evaporation of the solvents on a rotary evaporator.
The resulting EAF (2.3 g) was applied to a chromatographic
column on silica gel 60 (0.063-0.200 mm) (70–230 mesh)
and silica flash (35-75 μm) (220–440 mesh) and eluted with
a mixture of chloroform:methanol in increasing polarity,
yielding 54 fractions of 10 mL each. After a thin-layer chro-
matography (TLC) comparison, the fractions with similar
TLC patterns were grouped into ten sub-fractions. Sub-
fraction 5 (173 mg) was fractionated on a Sephadex LH-20
column using H2O, H2O:MeOH 1:1, and MeOH; this
process yielded two known flavonoids (6.5 mg and 5.8 mg).
A series of experiments was conducted to isolate the
acetogenin. Sub-fraction 8 (126 mg) was purified by
flash chromatography on silica gel 60 (0.063-0.200 mm)
(70–230 mesh) and silica flash (35-75 μm) (220–440 mesh)
to yield almunequin (8.4 mg).
The isolated compounds were identified by an analysis of
their nuclear magnetic resonance (NMR) data. NMR mea-
surements were conducted on a Varian Mercury Plus BB
spectrometer operating at 300 MHz for 1H and 75.5 MHz
for 13C using CD3OD and CDCl3 as the solvents and
tetramethylsilane (TMS) as the internal standard. The
1H NMR and 13C NMR data are in agreement with the
reported data for quercetin [43], luteolin [44], and almu-
nequin [32,45]:
Quercetin 1H NMR (300 MHz, CD3OD) δ ppm: 7.65
(1H, d, J = 1.8 Hz), 7.00 (1H, d, J = 8.9; 2.0 Hz), 6.9 (1H, d,
J = 8.9 Hz), 6.43 (1H, d, J = 2.1 Hz), 6.20 (1H, d, J = 2.1 Hz).
13C NMR (75.5 MHz, CD3OD) δ ppm: 158.5, 135.6, 179.4,
163.0, 99.9, 166.2, 94.8, 159.3, 104.7, 123.5, 117.6, 145.8,
149.3, 116.5, 123.1.
Luteolin 1H NMR (300 MHz, CD3OD) δ ppm: 7.43
(1H, d, J = 2 Hz), 6.68 (1H, d, J = 8.4; 1.8 Hz), 6.87 (1H, d,
J = 8.4 Hz), 6.39 (1H, d, J = 2.1 Hz), 6.20 (1H, d, J = 2.1 Hz).
13C NMR (75.5 MHz, CD3OD) δ ppm: 158.5, 135.6, 179.4,
163.0, 99.9, 166.2, 94.8, 159.3, 104.7, 123.5, 117.6, 145.8,
149.3, 116.5, 123.1.
Almunequin 1H NMR (300 MHz, CDCl3) δ ppm: 6.99
(1H, d, J = 1.2 Hz), 4.99 (1H, dq, J = 7.0; 1.2 Hz), 3.84
(5H, m), 3.60 (1H, m), 3.41 (2H, m), 2.25 (2H, t, J = 6.8 Hz),
2.00-1.60 (4H, m), 1.60-1.20 (m, CH2), 1.40 (3H, d, J = 6.9 Hz,
CH3), 0.87 (3H, t, J = 6.8 Hz, CH3);
13C NMR (75.5 MHz,
CDC13): 176.4, 148.8, 134.2, 83.2, 82.1, 81.9, 79.3, 77.3, 74.4,
72.0, 71.8, 37.3, 37.0, 35.6, 32.3, 29.5, 29.3, 29.1, 28.6, 28.34,
26.1, 25.6, 31.8, 27.3, 25.1, 22.5, 22.0, 19.1, 14.0.
Table 1 Plants (family and specimen), popular name, tested part (solvent), popular indication, and MICs of the extracts
tested in this study




Asteraceae Gochnatia polymorpha Less.
UPCB 30100ª
Cambará Bark (e) Antitussive [28] >500






Uterine inflammation [29] >250
Annonaceae Annona crassiflora Mart. DDMS4599b Araticum do cerrado L (m) Antidiarrheal [30] >250
Annona coriacea Mart. DDMS186b L (m) Antidiarrheal [31] >250
Annona sylvatica St.Hill DDMS4600b Araticum L (m) Antitussive, antipyretic,
antispasmodic [32]
184.33
Annona cacans Warm. DDMS Araticum-cagão,
Araticum-de-paca
L (m) >250







L (m) Antidiarrheal, antispasmodic [34] >250
Bignoniaceae Jacaranda decurrens Cham. Carobinha L (m) Astringent [35] >250




L (m) Antidiarrheal, anti-inflammatory,
antirheumatic
>250
Fabaceae Stryphnodendron adstringens (Mart.)
Coville DDMS152b
Barbatimão L (m), S (hs) Leucorrhoea, bleeding,
wound cleaning [36]
>250







Tuber (e) Antipyretic, diuretic, depurative [37] >250
Sinningia canescens (Mart.)
Wiehler MBM363740d
Rainha do abismo Tuber (e) >250
Malvaceae Hibiscus sabdariffa L. DDMS4593b Vinagreira, Azedinha L(e), C(e) Antispasmodic, anti-inflammatory,
antioxidant, diuretic, mild laxative [38]
>250





Myrtaceae Eugenia pyriformis Cambess.
UPCB 16741ª
Uvaia L (e) Astringent, digestive, antitumoral,
antimalarial, anti-inflammatory [40]
>250
Myrcia obtecta (O. Berg) Kiaersk.
var. obtecta UPCB50504a
Guamirim branco, Cambuí L (e) >250





L(m) Antidiarrheal and anti-inflammatory
[42]
>250
Rubiaceae Randia hebecarpa Benth. Limãozinho L(m) >250
Geophila repens (L.) I.M. Johnst. Cauá-pirí, Cauá-Pixi L(m) >250




Sapindaceae Serjania hebecarpa Benth. L(m) >250
Urvillea ulmaceae Kunth. L(m) >250
Tropaeolaceae Tropaeolum majus L. Capuchinha L(e), C(e),
R(hs)
>250
a.Herbarium of the Universidade Federal do Paraná – UFPR.
b.Herbarium of the Faculdade de Ciências Biológicas e Ambientais – UFGD/MS.
c.Herbarium of the Departamento de Biologia – UEM/PR.
d.Herbarium of the Museu Botânico Municipal de Curitiba - PR.
L = leaves; R = root (wood + bark); S = stem (wood + bark); C = capitulum; F = fruit.
Solvents: h, hexane; hs, 90% hydroethanolic solution; m, methanol; e, ethanol.
Araujo et al. BMC Complementary and Alternative Medicine 2014, 14:209 Page 3 of 10
http://www.biomedcentral.com/1472-6882/14/209
Araujo et al. BMC Complementary and Alternative Medicine 2014, 14:209 Page 4 of 10
http://www.biomedcentral.com/1472-6882/14/209Essential oil extraction
Fresh leaves of A. sylvatica, Trichilia silvatica, and S.
terebinthifolius were subjected to steam distillation for
3 h using a Clevenger-type apparatus. The oil was dried
by anhydrous sodium sulfate and preserved in a sealed
vial at 4°C until analysis.
LC-MS analysis of the methanolic extract of A. sylvatica
Studies using liquid chromatography coupled with mass
spectrometry (LC-MS) were performed using a quad MS
system spectrometer (Bruker, Bremen, Germany). Mass
spectrometry was carried out in positive mode, and nega-
tive ionization (ESI) was performed using a mass/charge
(m/z) ratio range from 60 to 1000. The sample was ana-
lyzed on an analytical LC system (Varian) with a ternary
solvent fitted with an automatic sample, a diode array
detector (PDA), and a mass spectrometer (Bruker). The
LC column was a Luna C-18 column (25 cm× 4.6 mm;
particle size, 5 μm) (Phenomenex, Torrance, CA, USA)
with a small pre-column (2.5 cm × 3 mm) containing the
same filling used to protect the analytical column. The
flow rate was 1.0 mL/min, and an injected volume of 10 L
was used for each analysis. All liquid chromatographic
analyses were performed at 22°C. The elution was con-
ducted using a solvent gradient of 0.1% formic acid:aceto-
nitrile (85:15, v/v); the elution required 40 min to reach
30% formic acid and 70% acetonitrile and was then
returned to the initial conditions in exactly 5 min.
Anti-M. tuberculosis activity
The anti-M. tuberculosis activity of the extracts, essential
oils, and compounds was determined using the REMA
method [46]. M. tuberculosis H37Rv ATCC 27294 was
grown for 15 days in Middlebrook 7H9 broth (Difco)
supplemented with OADC enrichment (BBL/Becton-
Dickinson) containing oleic acid, albumin, dextrose,
and catalase; 0.5% glycerol as a carbon source; and 0.5%
Tween 80 to prevent clumping. Suspensions were pre-
pared, and the turbidity was adjusted to a McFarland no. 1
standard.
Stock solutions of the tested extracts were prepared in
DMSO, and dilutions to obtain final concentrations
ranging from 0.98 to 250 μg/mL were prepared in
Middlebrook 7H9 broth supplemented with oleic acid,
albumin, dextrose, and catalase (OADC enrichment,
BBL/Becton-Dickinson, Sparks, MD, USA). Isoniazid,
rifampicin, streptomycin, and ethambutol were solubilized
according to the manufacturers’ recommendations (Difco
Laboratories, Detroit, MI, USA) and used as positive
control drugs.
After further dilutions to reach the final bacterial sus-
pension concentration (5×105 UFC/mL), 100 μL of the
inoculum was added to each well of a 96-well microtiter
plate containing the extracts. The assays were set up induplicate. The plates were incubated for 7 days at 37°C,
and after this incubation, 30 μL of 0.1 mg/mL resazurin
was added. The wells were read for color change and
fluorescence in a SPECTRAfluor Plus microfluorimeter
(TECAN) (excitation/emission with 530/590 nm filters,
respectively) after 24 h. The MIC (minimum inhibitory
concentration) was defined as the lowest concentration
resulting in a 90% growth inhibition of M. tuberculosis.
The MIC values of isoniazid (0.06 μg/mL), rifampicin
(0.03–0.06 μg/mL), streptomycin (0.25 μg/mL), and
ethambutol (2.0–4.00 μg/mL) were determined in a single
plate as standards [47].
A sample with an MIC value < 250 μg/mL was defined
as active against M. tuberculosis, and further analysis was
applied [48].
Animals and acute toxicity tests
Adult female Swiss mice (19 to 24 g) from the Federal
University of Grande Dourados were maintained at a
controlled temperature (23°C) and humidity (50%–60%)
with a constant 12 h light–dark cycle and free access to
food and water. The experimental procedures were in
accordance with the Ethical Principles in Animal Research
and approved by the Committee for Ethics in Animal
Experimentation at the Federal University of Grande
Dourados (Protocol no. 005/2010). The acute toxicity
studies were conducted according to OECD (Organization
for Economic Cooperation and Development) Guide-
line 425 [33] and ANVISA (Brazilian Health Surveillance
Agency) guidelines.
After 12 h of fasting, the animals were divided into four
groups. The treatments were performed by single oral ad-
ministration as doses of 0, 500, 1000, and 2000 mg/kg of
body weight of the EAF. The animals were observed for
signs of toxicity over 14 days. Behavioral parameters, mor-
tality, the weight of the animals, and the amount of water
and feed were analyzed.
After 14 days of treatment, the animals were weighed
and anesthetized (ketamine and xylazine, 25 and 10 mg/kg,
respectively). Blood samples were collected with and with-
out anticoagulant (heparin sodium, Cristália). The blood
samples were used to determine the hematological param-
eters (total and differential leukocyte count, hematocrit,
hemoglobin, and erythrocyte count), and the serum
samples were used for biochemical analysis (aspartate
aminotransferase – AST, alanine aminotransferase – ALT,
gamma glutamyl transferase – γ-GT, urea, and creatinine)
[49]. The biochemical parameters were determined by
spectrophotometry using Gold Analisa Diagnóstica
Ltda’s kits.
Subsequently, the animals were euthanized, and the vital
organs (lung, liver and right kidney) were removed and
weighed (absolute and relative weight). For the histo-
pathological analysis of these organs, the samples were
Table 2 MICa of A. sylvatica fractions and isolated
compounds against M. tuberculosis using the REMA assay
Fraction MIC (μg/mL) MIC (μM)
CF > 250 -
EAF 115.2 -
HMF > 250 -
Luteolin (1) 236.8 827.28
Quercetin (2) > 250 -





a:Values are means of duplicate sample.
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essed by conventional techniques in 5-mm-thick paraffin
slices. Slides were prepared and stained with hematoxylin
and eosin for light microscopy examination. The evaluated
parameters were reversible (degeneration) and irreversible
(necrosis and apoptosis) cell damage, leukocyte infiltra-
tion, congestion, blood extravasation, and fibrosis.
The data were evaluated using an analysis of variance
with an F-test, with p < 0.05 defined as significant.
Results and discussion
Antimycobacterial activity
The species and tested parts of the plants used in the
evaluation of anti-mycobacterial activity are shown in
Table 1. Of the 28 samples, only the crude extract from
A. sylvatica (MIC = 184.33 μg/mL) exhibited promising
activity (Table 1).
Several studies and screens must be performed to de-
velop a new drug for tuberculosis; therefore, many drug
discovery studies ultimately fail. A study in Mozambique
screened 75 extracts of medicinal plants used for the
local treatment of symptoms related to tuberculosis and
identified eight extracts with moderate to significant ac-
tivity against M. tuberculosis H37Rv. Of these extracts,
six showed MICs that were higher than those observed
for A. sylvatica and the A. sylvatica EAF. One extract
exhibited an MIC of 62 μg/mL, and another exhibited
an MIC of 15 μg/mL [16]. Another study evaluated the
anti-mycobacterial activity of the crude extract of Byrso-
nima crassa (leaves and bark) and obtained an MIC
value of 62.5 μg/mL for the chloroform extract of the
leaves. The chloroform extract of the bark presented an
MIC of 312.25 μg/mL [50].
The fractionation of the extract by partitioning in
different solvents provided the chloroform (CF), ethyl
acetate (EAF), and hydromethanol (HMF) fractions, which
were subsequently evaluated for their anti-mycobacterial
activity. An evaluation of the MIC of these fractions
(Table 2) revealed the potent activity of the EAF fraction,
with an MIC value of 115.2 μg/mL. The result of CIM of
standard drugs, used as a control to the antimycobacterial
activity tests are in agreement with the expected [47].
Brazilian flora is rich in plants of the family Annona-
ceae, which comprises approximately 120 genera and
2000–2200 species. This family is important as a source of
various edible fruits and seeds that can be used for the
production of edible oils. The major components identi-
fied in members of the Annonaceae are typically acetogen-
ins [51-53].
Annona sylvatica A.St.-Hill (formerly known as Rollinia
sylvatica St.-Hil. Mart) is a native Brazilian plant found in
Minas Gerais and São Paulo to Rio Grande do Sul. The
leaves of A. sylvatica have been used mainly as an antipyr-
etic in folk medicine. There are no reports in the literatureon the antimicrobial activity of this species, but studies
have reported that the essential oil obtained from the
leaves has anti-inflammatory activity and anticancer prop-
erties [54]. A chemical study reported the isolation of
sylvatin from Rollinia sylvatica [55]. Preliminary LC-MS
studies have shown that the major metabolites in the
leaves of A. sylvatica are flavonoids and acetogenins
(Figure 1).
The results of the present study indicate that the effects
of the methanolic extract of A. sylvatica and ethyl acetate
fraction may be associated with other components of the
extract (which were not evaluated) or that there might be
a synergism between the active isolated compounds.
Annonaceae acetogenins are secondary metabolites
derived from polyketides and are structurally charac-
terized by a long-chain terminal α, β-unsaturated methyl
γ-lactone. This hydrocarbon chain generally contains one,
two, or rarely three tetrahydrofuran (THF) rings. Aceto-
genins belong to two different classes: bis-tetrahydrofuran
non-adjacent almunequin and dihydroalmunequin 2.5 and
2, and β-hydroxy-methyl-γ-lactone and laherrandurin oti-
varin. The acetogenins identified in the extract of A. sylva-
tica have been reported in other Annona, including A.
atemoya and A. cherimola [45,56-58].
In this context, the present study revealed the potential
anti-M. tuberculosis activity of the methanolic extract of
A. sylvatica, which is still poorly characterized in phyto-
chemical and pharmacological terms. To characterize the
possible compounds responsible for this activity, we inves-
tigated the individual compounds in the methanolic ex-
tract of A. sylvatica; our chromatogram of the lyophilized
extract (Figure 1) showed characteristic distributions of
the flavonoids luteolin (m/z 286) (1) and quercetin (m/z
302) (2) and the acetogenins laherrandurin (m/z 624) (3),
almunequin (m/z 638) (4), otivarin (m/z 640) (5), and 2,5
dihydroalmunequin (m/z 640) (6) (Figure 1). This is the
Figure 1 Chromatogram of the lyophilized extract of leaves of A. sylvatica.
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from A. sylvatica leaves.
The isolated compounds evaluated for anti-mycobacterial
activity are shown in Table 2. In the present study, we
examined the effects of two flavonoids: luteolin and
quercetin. Among the isolated compounds, luteolin and
almunequin showed anti-M. tuberculosis effects, with
MIC values of 236.8 μg/mL (827.28 μM) and 209.9 μg/mL
(328.48 μM), respectively. Our data indicate that quer-
cetin, unlike luteolin and almunequin, failed to exhibit
anti-mycobacterial activity at low concentrations.
Luteolin isolated from the flowers of Chromolaena
odorata showed weak activity (699.3 μM MIC) against
M. tuberculosis [28]. However, luteolin isolated from
Ficus chlamydocarpa showed stronger activity against
M. tuberculosis and M. smegmatis (78.12 μg/mL MIC)
[29]. Nevertheless, the luteolin isolated from the whole
plant of Gentianopsis paludosa was inactive against these
microorganisms [30]. Having established the inhibitory
effects of luteolin on M. tuberculosis, we investigated
whether this agent exhibits a structure-activity relation-
ship in terms of its biological function. The isolated flavo-
noids belong to the flavone (luteolin) and flavon-3-ol
(quercetin) classes. The structures of quercetin and luteo-
lin share double bonds between C2 and C3 in ring C, the
3’, 4’ -diOH ring A groups, and the 7, 8 -diOH ring A
groups. However, ring C in these compounds shows
considerable variation, as it is a 3-OH group in quercetin.
This variation shows that catechol groups could notconfer appreciable activity when they were found on both
ring A and ring B. From a structural point of view, this
finding suggests that the 3-OH in quercetin results in an
inactivation of the structure, which might be critical
for M. tuberculosis survival. The observed results for
quercetin are consistent with those observed for quer-
cetin isolated from Helichrysum melanacme against
M. tuberculosis [31]. Based on our data and those of
others [31], we suggest that the absence of hydroxylation
in the C3 in structure of the luteolin is required for anti-
mycobacterial activity. These results may provide a basis
for the further design of new anti-mycobacterial drugs.
The compound almunequin was very difficult to isolate.
Almunequin is a C37 annonaceous acetogenin with a
bis-tetrahydrofuranic structure containing hydroxyl groups
and α, β-unsaturated γ-lactone methyl group. The struc-
ture-activity relationship for almunequin can be attributed
the α, β-unsaturated lactone present at the long-chain
terminal. The α, β-unsaturated lactones are a class of
synthetic and naturally occurring compounds that exhibit
a large spectrum of important pharmacological properties
[34-38,59].
Acute toxicity
The EAF fraction of A. sylvatica produced significant
weight gain in treated animals (Table 3). During treat-
ment, no clinical signs of toxicity were observed, and no
death was recorded. There were also no changes in food
or water intake. The oral administration of this fraction
Table 3 Body weight and relative weights of organs of animals exposed to EAF fraction
Parameters Control 500 mg kg−1 1000 mg kg−1 2000 mg kg−1 p*
Corporeal weight 21.09 ± 1.31 23.24 ± 1.71 22.24 ± 0.64 23.08 ± 0.74 0.0205
Liver 6.31 ± 0.45 5.98 ± 0.32 5.96 ± 0.70 5.89 ± 0.55 0.5294
Lungs 0.64 ± 0.06 0.56 ± 0.03 0.67 ± 0.15 0.68 ± 0.07 0.1458
Heart 0.47 ± 0.06 0.42 ± 0.02 0.43 ± 0.03 0.48 ± 0.03 0.0666
Right kidney 0.53 ± 0.05 0.58 ± 0.02 0.57 ± 0.05 0.57 ± 0.02 0.1773
Left kidney 0.56 ± 0.03 0.56 ± 0.02 0.59 ± 0.04 0.54 ± 0.08 0.7158
Spleen 0.53 ± 0.19 0.43 ± 0.02 0.48 ± 0.03 0.46 ± 0.04 0.5074
Relative weight (%) of the liver, lung, heart, right kidney, left kidney and spleen of female Swiss mice treated with 500, 1000 and 2000 mg kg−1 of the EAF fraction
of A. sylvatica. Data are expressed as the mean ± standard deviation SISVAR 5.3 [25]. (n=6) is the number of animals in each group. p*=5%.
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of adult female Swiss mice. Apart from the weight in-
crease, no visible clinical signs of toxicity were observed.
There was no evidence for differences in physiological
or behavioral responses between the control group and
any of the treated groups at any time. There were also
no differences in the consumption of food and water.
The hematologic parameters of the treated groups did
not differ from those of the control group. A biochemical
evaluation confirmed these results; there were no signifi-
cant differences in the AST, ALT, or γ GT results between
the control group and treated animals. These enzymes are
liver function markers, and changes in these parameters
may result from reversible or irreversible hepatocellularTable 4 Biochemical and hematological parameters of Swiss m
toxicity study
Parameters Control 500 mg kg−1
Creatinine (mg/dL) 0.29 ± 0.03 0.29 ± 0.07
Urea (mg/dL) 43.66 ± 4.27 44.33 ± 4.41
AST (U/L) 76 ± 4.45 78 ± 5.91
ALT (U/L 52.5 ± 4.27 48.5 ± 4.37
γ GT (U/L) 11 ± 1.41 11.5 ± 1.37
RBC (x 106/mm3) 7.06 ± 0.12 7.11 ± 0.11
HT (%) 45.33 ± 3.66 44.68 ± 3.55
WBC (%) 8.16 ± 0.75 8.33 ± 1.03
PLT (x 103/μL) 916 ± 10.78 928 ± 9.77
LYNF (%) 77 ± 1.63 71±1.36
NEUT (%) 19.16 ± 1.02 20 ± 1.69
Hematological and biochemical parameters of female Swiss mice treated acutely or
kg−1 1000 mg kg−1 and 2000 mg kg-1 Values represent the mean ± SD. (n=6) is the
AST = Aspartate aminotransferase.
ALT = Alanine aminotransferase.
γ GT = Gamma glutamyl transferase.
RBC = Red Blood Cell.
HT = Hematocrite.
WBC = White Blood Cell.
PLT= Platelets.
LYNF = Lymphocytes.
NEUT = Neutrophils.membrane damage. Changes in these markers are often
associated with necrosis, cholestasis, hypoxia, hypoper-
fusion, inflammation, infectious agents and toxins, or
excess lipid or glycogen deposition in hepatocytes
[39]. The integrity of liver function was assessed by
histopathological analysis of the liver, and we found
no damage associated with hepatotoxicity. The effects
of the acute administration of the EAF fraction of A.
sylvatica on hematological and biochemical parame-
ters are presented in Table 4.
The EAF fraction of A. sylvatica had no acute toxicity,
as evidenced by the absence of relevant clinical signs in
the toxicological screening and the absence of death
throughout the observation period. Hippocratic screeningice exposed to the EAF fraction of A. sylvatica in the acute
1000 mg kg−1 2000 mg kg−1 p*
0.28 ± 0.06 0.28 ± 0.05 0.8100
45 ± 5.03 42.5 ± 4.23 0.6391
77 ± 4.94 79 ± 4.99 0.9015
50 ± 4.27 53 ± 4.75 0.1990
11 ± 1.26 12 ± 12.6 0.5218
7.1 ± 0.10 7.15 ± 0.08 0.6161
44.5 ± 2.81 45.16 ± 3.9 0.9721
8 ± 0.63 8.33 ± 0.81 0.4138
928.66 ± 27 925.16 ± 13 0.5353
77.83 ± 0.89 79 ± 2.06 0.4913
19 ± 0.13 17 ± 1.14 0.5783
ally with vehicle (control) or the EAF fraction of A. sylvatica at doses of 500 mg
number of animals in each group. p*=5%.
Figure 2 Histological analysis of acute toxicity at doses of 500, 1000 and 2000 mg/kg-1 of EAF fraction (hematoxylin – eosin staining,
100X magnification). a) Longitudinal section of liver; b) longitudinal section of kidney.
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plants for toxicological and pharmacological activity. The
EAF fraction also did not have any influence on the con-
sciousness of the animals during the observed period. No
effects on the motor coordination or reflexes of the
treated animals were observed. At doses of 500, 1000,
and 2000 mg/kg, the EAF fraction produced no dose-
dependent changes in histopathology between the
control group and the treated animals (Figure 2). There-
fore, EAF has low toxicity at high doses in the short term.
Additional studies are required to determine the safety of
this fraction over a prolonged period.
The acute administration of the EAF produced no toxic
effects in adult female Swiss mice. No visible clinical signs
of toxicity, such as irritability, twisting, righting reflex,
tremors, convulsions, breathing, weight loss, or death,
were observed. In the present study, we did not observe
an increase in the accumulation of urea or creatinine.
These results were also confirmed by histopathological
analysis of the kidneys, which indicates that the acute
oral administration of A. sylvatica does not induce
nephrotoxicity.
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access permitted the researchers to collect botanical
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Medicinal Plants Garden of the Federal University ofGrande Dourados, and Gesneriaceae in the Municipal
Botanical Museum of Curitiba. The Rubiaceae were
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Conclusion
To the best of our knowledge, this is the first chemical
characterization, evaluation of antitubercular activity, and
analysis of the in vivo acute toxicity of the A. sylvatica
methanolic extract. Our study demonstrates the potential
anti-mycobacterial activity and the lack of in vivo acute
toxicity of its isolated compounds.
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